Joshua Friedman

Company: Spyre Therapeutics
Job title: Senior Vice President, Clinical Development
Seminars:
Advancing Combination Therapies to Change the Treatment Paradigm in IBD 4:30 pm
Scientific and clinical rationale for targeting ɑ4β7, TL1A, and IL-23 pathways in IBD therapy Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments Addressing the natural questions around patient selection for combination therapies: early hypotheses and future directionsRead more
day: Day One